A clinical-stage medical device company aiming to rapidly cool the brain to prevent ischemic injury has closed a seed round, raising $150K. NeuroSave, Inc. is developing a unique approach to therapeutic hypothermia, circulating cold fluid in the aerodigestive tract to cool blood in arteries traveling to the brain.
The company's technology is designed to deliver rapid, brain-targeted cooling while shielding the body from negative effects. Trials have demonstrated NeuroSave's ability to achieve cerebral cooling far faster than available non-surgical methods, creating a significant temperature difference between the brain and the body's core.
